Table 2.
Some of the available scores for outcome prediction of patients with colorectal liver metastases candidates to surgery
Morphology-based scores
|
Morphology- and Genetics-based scores
|
||||||
|
Nordlinger et al[18], 1996
|
CRS, Fong et al[19], 1999
|
Iwatsuki et al[20], 1999
|
Rees et al[21], 2008
|
RAS Mutation CRS, Brudvik et al[60] 2017
|
GAME score, Margonis et al[61] 2018
|
Extended CRS, Lang et al[65], 2019
|
Morphological parameters | |||||||
Age | Yes (60 yr) | ||||||
Primary tumor | |||||||
Extension into the serosa | Yes | ||||||
N status primary tumor | Yes | Yes | Yes | Yes | Yes | Yes | |
Grading primary tumor | Yes | ||||||
Liver metastases | |||||||
Number | Yes (3) | Yes (1) | Yes (2) | Yes (3) | Yes (TBS) | ||
Size | Yes (50 mm) | Yes (50 mm) | Yes (80 mm) | Yes (50 mm) | Yes (50 mm) | Yes (50 mm) | |
Bilobar | Y | ||||||
DFI | Yes (24 mo) | Yes (12 mo) | Yes (30 mo) | ||||
Surgical margin | Yes (10 mm) | ||||||
Extrahepatic disease | Yes | Yes | |||||
CEA value | Yes (200 ng/mL) | Yes (60 ng/mL) | Yes (20 ng/mL) | ||||
Genetic parameters | |||||||
RAS | Yes | Yes1 | |||||
RAS/RAF pathway | Yes | ||||||
SMAD | Yes |
KRAS status.
DFI: Disease-free interval from primary to metastases; CEA: Carcinoembryonic antigen; CRS: Clinical risk score; GAME: Genetic and morphological evaluation; TBS: Tumor Burden Score.